Key result
Preoperative PFT changes and COPD/CLD classifications were not associated with 30-day or 1-year mortality in TAVR, though decreased PO2 and elevated PCO2 increased 30-day risk.
Why the study?
The role of pulmonary function testing as a predictor of clinically relevant endpoints and for preoperative risk stratification in patients undergoing TAVR was unclear.
Does preoperative pulmonary function testing and COPD/CLD classification predict 30-day and 1-year all-cause mortality in patients undergoing TAVR?
Cohort (n=513)
Does preoperative pulmonary function testing and COPD/CLD classification predict 30-day and 1-year all-cause mortality in patients undergoing TAVR?
Isolated spirometry abnormalities and properly classified COPD do not predict 30-day or 1-year mortality after TAVR, whereas arterial blood gas abnormalities (PO2, PCO2, A-a gradient) are associated with 30-day mortality risk.
Answers are grounded in this paper and cite their sources.
PFT changes and COPD/CLD classifications should not yet inform TAVR risk stratification; leaves open whether arterial blood gas abnormalities warrant targeted preoperative evaluation.
BACKGROUND: The role of pulmonary function testing (PFT) as a predictor of clinically relevant endpoints in transcatheter aortic valve replacement (TAVR) is unclear. OBJECTIVE: To determine the utility of PFT in the preoperative risk stratification of patients undergoing TAVR. METHODS: An evaluation of PFT (i.e., FEV1), arterial blood gases (i.e., PO2), the diagnosis of chronic obstructive lung disease (COPD) by the Global Initiative for COPD (GOLD), and the diagnosis of chronic lung disease (CLD) by the Society of Thoracic Surgeons (STS) was performed to determine whether a relationship exists among these parameters and clinically relevant outcomes, including all-cause 30-day and 1-year mortality. RESULTS: A total of 513 patients underwent TAVR between March 2013 and December 2016. Per STS criteria, 269/513 (52%) had CLD with a mean FEV1 of 55.4 ± 12%. Per GOLD criteria, 158/513 (30%) of patients had COPD with a mean FEV1/forced vital capacity of 61.8 ± 8.2%. The severity of CLD was affected by changes in ejection fraction, albumin, creatinine, and B-type natriuretic peptide levels (p = .009, p < .001, p < .001, and p < .001, respectively), whereas the severity of COPD was not affected by these same variables, (p = .302, .079, .137, and .102, respectively). An increased A-a gradient (p = .035), increased PCO2 (p = .016), and decreased PO2 (p = <.001) demonstrated increased risk of 30-day mortality. Neither classification (COPD or CLD), nor PFT changes, showed association with 30-day and 1-year mortality (p = NS). CONCLUSION: This study suggests that isolated abnormalities in spirometry are a poor indicator of clinically relevant outcomes in TAVR. When classified correctly, COPD does not predict clinically relevant postoperative outcomes.
No takes yet. Share an insight, caveat, or question.
Pino et al. (2019) conducted a cohort in Patients undergoing transcatheter aortic valve replacement (TAVR) (n=513). Preoperative pulmonary function testing (FEV1), arterial blood gases (PO2, PCO2, A-a gradient), and COPD/CLD classification vs. Normal spirometry / absence of COPD or CLD was evaluated on All-cause 30-day and 1-year mortality (p=NS). Preoperative PFT changes and COPD/CLD classifications were not associated with 30-day or 1-year mortality in TAVR, though decreased PO2 and elevated PCO2 increased 30-day risk.
Synapse has enriched 10 related papers. Consider them for comparative context: